Perspective Therapeutics (CATX) News Today → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free CATX Stock Alerts $1.38 +0.06 (+4.55%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 1:22 AM | americanbankingnews.comPerspective Therapeutics (NYSE:CATX) Shares Gap Up After Insider Buying ActivityJune 1 at 6:50 AM | americanbankingnews.comRobert F. Williamson III Acquires 30,031 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockMay 31 at 10:33 AM | marketbeat.comPerspective Therapeutics (NYSE:CATX) Shares Gap Up Following Insider Buying ActivityPerspective Therapeutics (NYSE:CATX) Shares Gap Up Following Insider Buying ActivityMay 31 at 9:30 AM | insidertrades.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III Buys 30,031 SharesMay 30 at 4:40 PM | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Purchases $39,941.23 in StockPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Robert F. Williamson III acquired 30,031 shares of the business's stock in a transaction on Wednesday, May 29th. The shares were purchased at an average price of $1.33 per share, for a total transaction of $39,941.23. Following the purchase, the director now directly owns 368,792 shares of the company's stock, valued at $490,493.36. The transaction was disclosed in a filing with the SEC, which is available through this link.May 27, 2024 | seekingalpha.comPerspective Therapeutics: An Elevated Theranostics Play Flying Under Your RadarMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Promising Competitor Data and Treatment InnovationsMay 24, 2024 | globenewswire.comPerspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMay 20, 2024 | insidertrades.comInsider Trading is Good News for These StocksMay 20, 2024 | insidertrades.comInsider Trading is Good News for These StocksMay 20, 2024 | globenewswire.comPerspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024May 17, 2024 | bizjournals.comGT Medical Technologies acquires cancer treatment subsidiary from Seattle companyMay 17, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 6.5%Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 6.5%May 16, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Sees Large Volume IncreasePerspective Therapeutics (NYSEAMERICAN:CATX) Sees Unusually-High Trading VolumeMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)May 15, 2024 | bizjournals.comPerspective Therapeutics sells subsidiary to Arizona companyMay 15, 2024 | marketbeat.comPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Large Growth in Short InterestPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 13,590,000 shares, an increase of 30.3% from the April 15th total of 10,430,000 shares. Based on an average daily trading volume, of 4,400,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 2.9% of the company's stock are short sold.May 15, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Sets New 12-Month High at $1.91Perspective Therapeutics (NYSEAMERICAN:CATX) Reaches New 1-Year High at $1.91May 15, 2024 | investorplace.comCATX Stock Earnings: Perspective Therapeutics Meets EPS for Q1 2024May 15, 2024 | washingtonpost.comPerspective Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsMay 14, 2024 | msn.comRBC Capital Initiates Coverage of Perspective Therapeutics (CATX) with Outperform RecommendationMay 14, 2024 | marketbeat.comPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of "Buy" from BrokeragesPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) has received a consensus recommendation of "Buy" from the five brokerages that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. Several research analMay 14, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Earns Outperform Rating from Analysts at Royal Bank of CanadaRoyal Bank of Canada initiated coverage on shares of Perspective Therapeutics in a research report on Tuesday. They issued an "outperform" rating and a $3.00 price objective for the company.May 13, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.9% Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 4.9%May 9, 2024 | msn.comCantor Fitzgerald Initiates Coverage of Perspective Therapeutics (CATX) with Overweight RecommendationMay 9, 2024 | marketbeat.comPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Expected to Post FY2024 Earnings of ($0.12) Per SharePerspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) - Analysts at Lifesci Capital issued their FY2024 earnings estimates for shares of Perspective Therapeutics in a research note issued on Monday, May 6th. Lifesci Capital analyst A. Dhankher forecasts that the company will post earniMay 9, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Earns Overweight Rating from Analysts at Cantor FitzgeraldCantor Fitzgerald began coverage on shares of Perspective Therapeutics in a research note on Thursday. They set an "overweight" rating on the stock.May 3, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming May Investor ConferencesMay 2, 2024 | markets.businessinsider.comThe Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 ExpertsMay 2, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Sets New 1-Year High at $1.87Perspective Therapeutics (NYSEAMERICAN:CATX) Hits New 1-Year High at $1.87May 2, 2024 | finance.yahoo.comPerspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comPerspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsApril 30, 2024 | globenewswire.comPerspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsApril 29, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 6.6%Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 6.6%April 23, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Hits New 12-Month High at $1.62Perspective Therapeutics (NYSEAMERICAN:CATX) Sets New 52-Week High at $1.62April 16, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 7.2%Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Down 7.2%April 15, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 3.7%Perspective Therapeutics (NYSEAMERICAN:CATX) Trading 3.7% HigherApril 12, 2024 | marketbeat.comQ1 2024 EPS Estimates for Perspective Therapeutics, Inc. Raised by B. Riley (NYSEAMERICAN:CATX)Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) - Equities researchers at B. Riley lifted their Q1 2024 earnings estimates for Perspective Therapeutics in a research note issued to investors on Tuesday, April 9th. B. Riley analyst Y. Zhi now expects that the company will post earApril 11, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Sees Unusually-High Trading VolumePerspective Therapeutics (NYSEAMERICAN:CATX) Sees Strong Trading VolumeApril 9, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Price Target Raised to $1.70B. Riley increased their price objective on Perspective Therapeutics from $1.20 to $1.70 and gave the company a "buy" rating in a research report on Tuesday.April 8, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming April Investor ConferencesApril 6, 2024 | marketbeat.comPerspective Therapeutics (NYSEAMERICAN:CATX) Sets New 12-Month High at $1.60Perspective Therapeutics (NYSEAMERICAN:CATX) Sets New 52-Week High at $1.60April 1, 2024 | marketbeat.comPerkins Capital Management Inc. Lowers Holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)Perkins Capital Management Inc. trimmed its holdings in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) by 73.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 700,000 shareApril 1, 2024 | marketbeat.comPerspective Therapeutics' (CATX) Outperform Rating Reiterated at OppenheimerOppenheimer restated an "outperform" rating and set a $1.50 price target (up from $1.20) on shares of Perspective Therapeutics in a research report on Monday.March 28, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsMarch 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Clinical Success and Strategic PartnershipsMarch 19, 2024 | wsj.comPerspective Therapeutics Inc.March 19, 2024 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)Oppenheimer reissued an "outperform" rating and issued a $1.20 price target on shares of Perspective Therapeutics in a report on Tuesday.March 18, 2024 | msn.comPerspective Therapeutics partners with Bristol Myers for its metastatic melanoma treatment study Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (Ad)Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with … Find out details on these three critical Nvidia partners immediately. CATX Media Mentions By Week CATX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼1.120.77▲Average Medical News Sentiment CATX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼72▲CATX Articles Average Week Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AXNX News PRCT News TNDM News NARI News IRTC News ICUI News IART News NVCR News UFPT News LMAT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CATX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Gates is all about this tiny $2 stockTimothy SykesBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTradeShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
